MCID: SPR168
MIFTS: 21

Supratentorial Ependymoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Supratentorial Ependymoma

MalaCards integrated aliases for Supratentorial Ependymoma:

Name: Supratentorial Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080890

Summaries for Supratentorial Ependymoma

Disease Ontology : 12 A high grade ependymoma that is located within the supratentorial brain.

MalaCards based summary : Supratentorial Ependymoma is related to rela fusion-positive ependymoma and pediatric supratentorial ependymoma. An important gene associated with Supratentorial Ependymoma is CD274 (CD274 Molecule). The drugs Mesna and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include brain.

Related Diseases for Supratentorial Ependymoma

Graphical network of the top 20 diseases related to Supratentorial Ependymoma:



Diseases related to Supratentorial Ependymoma

Symptoms & Phenotypes for Supratentorial Ependymoma

Drugs & Therapeutics for Supratentorial Ependymoma

Drugs for Supratentorial Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 2 3375-50-6 598
2
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
3
Etoposide Approved Phase 2 33419-42-0 36462
4
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
5
Lenograstim Approved, Investigational Phase 2 135968-09-1
6
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
7
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
8
Molgramostim Investigational Phase 2 99283-10-0
9 Tubulin Modulators Phase 2
10 Etoposide phosphate Phase 2
11 acivicin Phase 2
12 Immunosuppressive Agents Phase 2
13 Alkylating Agents Phase 2
14 Immunologic Factors Phase 2
15 Adjuvants, Immunologic Phase 2
16 Antirheumatic Agents Phase 2
17 Keratolytic Agents Phase 2
18 Dermatologic Agents Phase 2
19 Antimitotic Agents Phase 2
20 Podophyllotoxin Phase 2 518-28-5

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna

Search NIH Clinical Center for Supratentorial Ependymoma

Genetic Tests for Supratentorial Ependymoma

Anatomical Context for Supratentorial Ependymoma

MalaCards organs/tissues related to Supratentorial Ependymoma:

40
Brain

Publications for Supratentorial Ependymoma

Articles related to Supratentorial Ependymoma:

(show top 50) (show all 72)
# Title Authors PMID Year
1
YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. 61
33074854 2021
2
Supratentorial ependymoma in childhood: more than just RELA or YAP. 61
33481105 2021
3
ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. 61
33741710 2021
4
ZFTA-translocations constitute ependymoma chromatin remodeling and transcription factors. 61
33741711 2021
5
Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma. 61
33576087 2021
6
Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features. 61
33221956 2021
7
Supratentorial ependymoma with YAP1:FAM118B fusion: A case report. 61
33480048 2021
8
Correction to: C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma. 61
33095338 2020
9
C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma. 61
32909151 2020
10
Continuous Intravenous Lidocaine Provides Effective Pain Control in a Palliative Child: A Case Report. 61
32909728 2020
11
Conventional and Advanced Magnetic Resonance Imaging Features of Supratentorial Extraventricular Ependymomas. 61
32842060 2020
12
Fahr's disease associated with anaplastic ependymoma: a case report and review of the literature. 61
32909453 2020
13
Influence of Target Location, Size, and Patient Age on Normal Tissue Sparing- Proton and Photon Therapy in Paediatric Brain Tumour Patient-Specific Approach. 61
32927700 2020
14
CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. 61
32514758 2020
15
YAP1/TAZ drives ependymoma-like tumour formation in mice. 61
32404936 2020
16
Prognostic value of H3K27me3 in children with ependymoma. 61
31850684 2020
17
MYCN amplification drives an aggressive form of spinal ependymoma. 61
31414211 2019
18
MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. 61
30027327 2019
19
Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. 61
30976811 2019
20
YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. 61
31477715 2019
21
Pediatric Supratentorial Ependymoma: Surgical, Clinical, and Molecular Analysis. 61
29917116 2019
22
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. 61
30811284 2019
23
A Case of Recurrent Supratentorial Extraventricular Anaplastic Ependymoma in Adult. 61
31062531 2019
24
A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review. 61
30631904 2019
25
Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma. 61
30483834 2019
26
Surgical outcome in cortical ependymoma: A single centre experience of 18 cases. 61
30528353 2019
27
[Ependymoma in Sellar Region:Report of One Case]. 61
30837057 2019
28
Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology. 61
29266023 2019
29
Sulfonylurea receptor 1 expression is variable in adult and pediatric brain tumors. 61
30079884 2018
30
A Mouse Ependymoma Model Provides Molecular Insights into Tumor Formation. 61
29949754 2018
31
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. 61
29350470 2018
32
Establishing a Preclinical Multidisciplinary Board for Brain Tumors. 61
29301833 2018
33
Supratentorial Pure Cortical Ependymoma: An Unusual Lesion Causing Focal Motor Aware Seizure. 61
29725181 2018
34
Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. 61
29440180 2018
35
Aggressive Supratentorial Ependymoma, RELA Fusion-Positive with Extracranial Metastasis: A Case Report. 61
29161788 2017
36
Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases. 61
27395057 2017
37
Toward an integrated histomolecular diagnosis of supratentorial ependymoma. 61
27044295 2016
38
The Similarities and Differences between Intracranial and Spinal Ependymomas : A Review from a Genetic Research Perspective. 61
26962412 2016
39
Imaging characteristics of supratentorial ependymomas: Study on a large single institutional cohort with histopathological correlation. 61
26425155 2015
40
[Classification of gliomas. Current progress and perspectives]. 61
25989737 2015
41
EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. 61
25586788 2015
42
C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. 61
25388523 2015
43
Supratentorial ependymoma presenting as a cortical cyst with a mural nodule in an adult. 61
25589537 2015
44
The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience. 61
25391979 2015
45
Supratentorial ependymoma with glial component of two different histologies and neuropil-like islands: a case report. 61
24424113 2014
46
C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. 61
24553141 2014
47
Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. 61
24057324 2013
48
Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. 61
24101739 2013
49
Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" III prospective clinical trial. 61
23508296 2013
50
Supratentorial ependymoma: disease control, complications, and functional outcomes after irradiation. 61
23245280 2013

Variations for Supratentorial Ependymoma

Expression for Supratentorial Ependymoma

Search GEO for disease gene expression data for Supratentorial Ependymoma.

Pathways for Supratentorial Ependymoma

GO Terms for Supratentorial Ependymoma

Biological processes related to Supratentorial Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.26 RELA CD274
2 response to cytokine GO:0034097 9.16 RELA CD274
3 response to progesterone GO:0032570 8.96 YAP1 RELA
4 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 8.62 YAP1 RELA

Sources for Supratentorial Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....